Seres Therapeutics (NASDAQ:MCRB) Share Price Passes Above 50-Day Moving Average of $0.84

Seres Therapeutics, Inc. (NASDAQ:MCRBGet Free Report) crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $0.84 and traded as high as $1.09. Seres Therapeutics shares last traded at $1.08, with a volume of 1,822,929 shares.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on MCRB shares. Oppenheimer cut their price objective on shares of Seres Therapeutics from $5.00 to $4.00 and set an “outperform” rating for the company in a report on Thursday, May 9th. Chardan Capital reduced their price target on Seres Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, May 8th.

Check Out Our Latest Research Report on Seres Therapeutics

Seres Therapeutics Price Performance

The company’s fifty day simple moving average is $0.84 and its 200-day simple moving average is $1.02. The firm has a market capitalization of $163.57 million, a PE ratio of -1.80 and a beta of 1.95.

Seres Therapeutics (NASDAQ:MCRBGet Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.09. Analysts forecast that Seres Therapeutics, Inc. will post -1.02 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Seres Therapeutics in the first quarter valued at about $39,000. Tower Research Capital LLC TRC lifted its stake in Seres Therapeutics by 668.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 38,091 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 33,135 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Seres Therapeutics during the 4th quarter worth approximately $73,000. Virtu Financial LLC purchased a new stake in shares of Seres Therapeutics in the first quarter valued at approximately $73,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Seres Therapeutics in the third quarter valued at approximately $120,000. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

(Get Free Report)

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.

Featured Stories

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.